Tyra Biosciences (NASDAQ:TYRA) Price Target Cut to $30.00 by Analysts at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its price objective decreased by research analysts at HC Wainwright from $32.00 to $30.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 86.68% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target for the company. Oppenheimer boosted their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $22.00 to $31.00 in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock traded down $0.04 on Monday, reaching $16.07. 16,365 shares of the company were exchanged, compared to its average volume of 189,443. Tyra Biosciences has a 1-year low of $10.60 and a 1-year high of $29.60. The firm has a market cap of $848.66 million, a price-to-earnings ratio of -9.74 and a beta of 1.08. The company’s 50-day moving average is $21.86 and its two-hundred day moving average is $20.00.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 11,078 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the transaction, the director now owns 472,207 shares of the company’s stock, valued at $7,635,587.19. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the sale, the director now directly owns 472,207 shares of the company’s stock, valued at $7,635,587.19. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alan Fuhrman bought 9,500 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 101,050 shares of company stock worth $2,235,492 over the last quarter. 15.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. Rhumbline Advisers increased its position in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of Tyra Biosciences by 9.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after buying an additional 6,318 shares in the last quarter. Jennison Associates LLC increased its holdings in Tyra Biosciences by 5.9% in the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after buying an additional 8,837 shares during the last quarter. SG Americas Securities LLC bought a new position in Tyra Biosciences during the third quarter valued at approximately $311,000. Finally, Bank of New York Mellon Corp lifted its stake in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.